학술논문
First-in-class drug candidate (MPH-220) efficiently improves spastic gait disorders by selective inhibition of fast skeletal muscle myosin-2
Document Type
Abstract
Author
Source
In Biophysical Journal 11 February 2022 121(3) Supplement 1:291a-291a
Subject
Language
ISSN
0006-3495